Sequence of cardiovascular autonomic alterations after fingolimod initiation.

about

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis.

P2860

Q42694313-903BFB74-B3D8-45A6-9354-881BF8947C4F

P2860

Sequence of cardiovascular autonomic alterations after fingolimod initiation.

Item

http://www.wikidata.org/entity/Q48248422

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Sequence of cardiovascular autonomic alterations after fingolimod initiation.

@en

Sequence of cardiovascular autonomic alterations after fingolimod initiation.

@nl

type

Item

label

Sequence of cardiovascular autonomic alterations after fingolimod initiation.

@en

Sequence of cardiovascular autonomic alterations after fingolimod initiation.

@nl

prefLabel

Sequence of cardiovascular autonomic alterations after fingolimod initiation.

@en

Sequence of cardiovascular autonomic alterations after fingolimod initiation.

@nl

P1476

Sequence of cardiovascular autonomic alterations after fingolimod initiation

@en

P2093

Juha E K Hartikainen

http://www.w3.org/2001/XMLSchema#string

Päivi Hartikainen

http://www.w3.org/2001/XMLSchema#string

Tiina M Laitinen

http://www.w3.org/2001/XMLSchema#string

Tomi P Laitinen

http://www.w3.org/2001/XMLSchema#string

P2860

Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications

Vagomimetic effects of fingolimod: physiology and clinical implications

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects

Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology

Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

Oral fingolimod (FTY720) for relapsing multiple sclerosis.

P31

scholarly article

P356

10.1111/ANEC.12443

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sakari Simula

P577

2017-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28191684

http://www.w3.org/2001/XMLSchema#string

P932

6931564

http://www.w3.org/2001/XMLSchema#string

Sequence of cardiovascular autonomic alterations after fingolimod initiation.

about

P2860

P2860

Sequence of cardiovascular autonomic alterations after fingolimod initiation.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P433

P478

P50

P577

P698

P932